|
||
| The Copaxone News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| March 2005 | |||||
| June 2005 | |||||
| July 2005 | |||||
| August 2005 | |||||
| October 2005 | |||||
| November 2005 | |||||
| December 2005 | |||||
| January 2006 | |||||
| February 2006 | |||||
| May 2006 | |||||
| June 2006 | |||||
| August 2006 | |||||
| October 2006 | |||||
| November 2006 | |||||
| December 2008 | |||||
| January 2013 | |||||
| May 2013 | |||||
| June 2013 | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| November 2013 | |||||
| November 2014 | |||||
| December 2014 | |||||
| January 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| February 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Monday
Breaking News on Copaxone...plus 2 new treatments: oral laquinimod & ATL/TV1102
The following story was posted today on our MS News
Channel MySpace Blog.
It is one of 4,613 stories on our MySpace Blog! Our 3,300 MySpace Friends
have made 29,896 Comments & 42,234 Kudos on the 4,613 stories!
CLICK HERE TO VIEW THE MYSPACE BLOG & LEAVE A COMMENT
***********Press Release*************
TEVA TO PRESENT NEW TREATMENT DATA AT WORLD CONGRESS FOR MULTIPLE SCLEROSIS
Jerusalem, Israel, September 15, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal. New data will be presented on COPAXONE® (glatiramer acetate injection), a leading therapy for relapsing-remitting multiple sclerosis (RRMS) treatment, covering early treatment with COPAXONE®, long-term efficacy and safety.
In addition to Teva's post-marketing studies of COPAXONE® in RRMS, the company will also present data on oral laquinimod, which is now being investigated in 2 global Phase III studies (www.tevaclinicaltrials.com) and on ATL/TV1102, a second-generation VLA-4 inhibitor which has recently published positive results from a Phase IIa study in RRMS patients.
Teva's extensive work and continuous investments exemplified by these presentations represents the Company's commitment to research that advances the understanding of MS and its goal to seek improved therapies to address unmet needs within the category. Teva R&D efforts in this area include a breadth of pipeline compounds focused on various areas of discovery which hold promise for the treatment of MS.
Platform Presentations/Poster Sessions
COPAXONE® Clinical Studies
" Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial (Presentation 17, September 18 at 11:40 AM)
" Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome (CIS): subgroup analyses (Presentation 32, September 18 at 3:30 PM)
" Continuous Long-Term Immunomodulatory Therapy in Relapsing Multiple Sclerosis: Results from the 15 year Analysis of the US Prospective Open-label Study of Glatiramer Acetate (Presentation 44, September 18 at 3:30 PM)
" The impact of long-term treatment with disease modifying therapy on disability progression in relapsing-remitting multiple sclerosis patients (Presentation 26, September 18 at 3:30 PM)
" Long-term follow-up of immunomodulatory therapies in early relapsing-remitting multiple sclerosis (Presentation 57, September 18 at 3:30 PM)
" Fatigue in relapsing-remitting multiple sclerosis - assessment of clinical neuropsychological and immunological parameters in patients treated with glatiramer acetate (Presentation 478, September 19 at 3:30 PM)
" Glatiramer Acetate Reduces Multiple Sclerosis Severity: Analysis of Patients from the US Pivotal Studies Using the Multiple Sclerosis Severity Scale (Presentation 454, September 19 at 3:30 PM)
" Short-term Immunosuppression with Mitoxantrone Followed by Long-term Glatiramer Acetate vs. Glatiramer Acetate Alone: Results at 36 Months in Patients with Relapsing-Remitting Multiple Sclerosis (Presentation 3, September 18 at 3:30 PM)
Laquinimod
" Oral Laquinimod in Patients with Relapsing-Remitting Multiple Sclerosis: 9-month double-blind active extension of the Multi-center, Randomized, Double-blind, Parallel-group Placebo-controlled Study (Presentation 31, September 18 at 3:30 PM)
" Laquinimod given before and after disease onset reduces inflammatory cell infiltration and demyelination in experimental autoimmune encephalomyelitis (Presentation 842, September 19 at 3:30 PM)
ATL/TV1102
" VLA-4 antisense: an oligonucleotide targeting VLA-4 mRNA (ATL1102) significantly reduces new active lesions in patients with relapsing-remitting multiple sclerosis (Presentation 81, late-breaking news, September 20 at 9:15 AM)
Channel MySpace Blog.
It is one of 4,613 stories on our MySpace Blog! Our 3,300 MySpace Friends
have made 29,896 Comments & 42,234 Kudos on the 4,613 stories!
CLICK HERE TO VIEW THE MYSPACE BLOG & LEAVE A COMMENT
***********Press Release*************
TEVA TO PRESENT NEW TREATMENT DATA AT WORLD CONGRESS FOR MULTIPLE SCLEROSIS
Jerusalem, Israel, September 15, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal. New data will be presented on COPAXONE® (glatiramer acetate injection), a leading therapy for relapsing-remitting multiple sclerosis (RRMS) treatment, covering early treatment with COPAXONE®, long-term efficacy and safety.
In addition to Teva's post-marketing studies of COPAXONE® in RRMS, the company will also present data on oral laquinimod, which is now being investigated in 2 global Phase III studies (www.tevaclinicaltrials.com) and on ATL/TV1102, a second-generation VLA-4 inhibitor which has recently published positive results from a Phase IIa study in RRMS patients.
Teva's extensive work and continuous investments exemplified by these presentations represents the Company's commitment to research that advances the understanding of MS and its goal to seek improved therapies to address unmet needs within the category. Teva R&D efforts in this area include a breadth of pipeline compounds focused on various areas of discovery which hold promise for the treatment of MS.
Platform Presentations/Poster Sessions
COPAXONE® Clinical Studies
" Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial (Presentation 17, September 18 at 11:40 AM)
" Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome (CIS): subgroup analyses (Presentation 32, September 18 at 3:30 PM)
" Continuous Long-Term Immunomodulatory Therapy in Relapsing Multiple Sclerosis: Results from the 15 year Analysis of the US Prospective Open-label Study of Glatiramer Acetate (Presentation 44, September 18 at 3:30 PM)
" The impact of long-term treatment with disease modifying therapy on disability progression in relapsing-remitting multiple sclerosis patients (Presentation 26, September 18 at 3:30 PM)
" Long-term follow-up of immunomodulatory therapies in early relapsing-remitting multiple sclerosis (Presentation 57, September 18 at 3:30 PM)
" Fatigue in relapsing-remitting multiple sclerosis - assessment of clinical neuropsychological and immunological parameters in patients treated with glatiramer acetate (Presentation 478, September 19 at 3:30 PM)
" Glatiramer Acetate Reduces Multiple Sclerosis Severity: Analysis of Patients from the US Pivotal Studies Using the Multiple Sclerosis Severity Scale (Presentation 454, September 19 at 3:30 PM)
" Short-term Immunosuppression with Mitoxantrone Followed by Long-term Glatiramer Acetate vs. Glatiramer Acetate Alone: Results at 36 Months in Patients with Relapsing-Remitting Multiple Sclerosis (Presentation 3, September 18 at 3:30 PM)
Laquinimod
" Oral Laquinimod in Patients with Relapsing-Remitting Multiple Sclerosis: 9-month double-blind active extension of the Multi-center, Randomized, Double-blind, Parallel-group Placebo-controlled Study (Presentation 31, September 18 at 3:30 PM)
" Laquinimod given before and after disease onset reduces inflammatory cell infiltration and demyelination in experimental autoimmune encephalomyelitis (Presentation 842, September 19 at 3:30 PM)
ATL/TV1102
" VLA-4 antisense: an oligonucleotide targeting VLA-4 mRNA (ATL1102) significantly reduces new active lesions in patients with relapsing-remitting multiple sclerosis (Presentation 81, late-breaking news, September 20 at 9:15 AM)